CD4 and cervical cancer: In contrast, CD4+ responses were more frequent among the women with no CIN (50%; six out of 12) or with cervical cancer (60%; three out of five), than among those with low-grade (37.5%; three out of eight) and high-grade disease (25%; four out of 16) (Figure 2C).